7:15 am Registration & Coffee Room Networking
Accelerating the Future of the Allogeneic Field with Novel Innovation, Strategy & Clinical Data
8:15 am Opening Remarks
8:30 am Industry Leaders Fireside Chat: Highlights & Hurdles from the Past Year to Inform Your 2024 Strategy
9:00 am Full Landscape Overview of the Allogeneic Cell Therapy Space
9:30 am Caribou Biosciences: Pre-Clinical & Clinical Data Presentation
10:00 am Morning Refreshment Break & Speed Networking
Synopsis
As the allogeneic community is reunited, this session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the 3 different tracks: Pre-Clinical, Clinical and Manufacturing & Process Development
PRE-CLINICAL TRACK
Improving Pre-Clinical Models to Better Prepare Allogeneic Therapies for the Clinic
11:30 am Innovative Model Strategies for Enhanced Translatability & Predictivity vs. Traditional Approaches in Pre-Clinical Research
12:00 pm Exploring the Applications of B-Cells in Novel Off-theShelf Therapies
CLINICAL TRACK
Implementing Effective Allogeneic Donor Selection & Management
11:30 am Insights from INB-100 Trial Expansion Cohort: Unveiling Progress & Challenges
12:00 pm Dose Escalation for Allogeneic CAR-T Cell Therapies, Clinical & Translational Updates
MANUFACTURING & PROCESS DEVELOPMENT TRACK
Upscaling Manufacturing for Allogeneic Cell Therapies to Meet Rising Demands
11:30 am What are the Opportunities for Using Automation in Upscaling Allogeneic Manufacturing?
12:00 pm Using Agile Process Development to De-Risk the Upscaling of Your Manufacturing Process
12:30 pm Lunch Refreshment
2:00 pm Leveraging In Vitro Models to Streamline Transition to the Clinic
Revolutionary Novel Modifications to Enhance the Potency of Off-the-Shelf Therapies
2:30 pm Evolving Cell Constructs Beyond CAR to Make Truly Off-the-Shelf Cell Therapies
3:00 pm Innovative Strategies for Improving Potency of Allogeneic Gamma Delta Cell Therapies
3:30 pm Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR-T Therapies
2:00 pm Clinical Safety & Immunogenicity Monitoring Strategies for Edited CAR-T Cell Therapy
Spotlighting Recent Allogeneic Clinical Successes
2:30 pm Reporting Clinical Data from a First-in-Class Plasmacytoid Dendritic Cell Line Vaccine in Patients with Metastatic NSCLC
3:00 pm Expanding a Clinically Informed Pipeline in Autoimmune Diseases & Oncology
3:30 pm Panel Discussion: Is the Future for Allogeneic Therapies as Mono-Therapy or Combination?
2:00 pm Preparing Your Supply Chain for Growing Demand for Allogeneic Products
Sourcing & Selecting Optimal Starting Material for Allogeneic Engineering
2:30 pm Unveiling the Role of iPSCs in the Advancement of Allogeneic Cell Therapies
3:00 pm Characterizing Starting Material for Safety & Efficacy
3:30 pm Panel Discussion: What Criteria Make the Ideal Starting Material for Allogeneic Products?
4:00 pm Afternoon Break & Tech Slam
5:00 pm Sanofi: Clinical Data Presentation
5:30 pm Overcoming Hurdles in Allogeneic Cell Therapy Development Using Pooled Donor Cord Blood CD34+ Cells as the Starting Material
6:00 pm Closing Remarks & End of Day One
6:15 pm Drinks Reception
Synopsis
Reunite with old friends and meet new industry peers after a busy day of innovation.